West Pharmaceutical Services (WST) Cash from Investing Activities (2009 - 2026)

West Pharmaceutical Services (WST) has reported Cash from Investing Activities for 18 consecutive years, with -$43.2 million the latest figure, recorded in Q2 2026.

• Quarterly Cash from Investing Activities rose 42.55% year-over-year to -$43.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$225.3 million (up 32.42% YoY) and the FY2025 annual result came in at -$285.9 million, up 24.5% from the prior year.
• Cash from Investing Activities retreated to -$43.2 million in Q2 2026 per WST's latest filing, from -$42.7 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for WST reached as high as -$42.7 million in Q1 2026 and fell as low as -$108.8 million in Q4 2023.
• A 5-year average of -$78.2 million and a median of -$79.1 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 61.93% — and 2026, when it surged 42.55%.
• Year by year, Cash from Investing Activities stood at -$94.8 million in 2022, then decreased by 14.77% to -$108.8 million in 2023, then gained by 3.68% to -$104.8 million in 2024, then grew by 27.39% to -$76.1 million in 2025, then soared by 43.23% to -$43.2 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$43.2 million, -$42.7 million, and -$76.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.